19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensive Cardiometabolic Regulation Capabilities

🇨🇳 Laotian Times (CN) —
19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensive Cardiometabolic Regulation Capabilities

AI Summary

BrightGene Bio-Medical has reported significant results from a Phase III clinical trial of its GLP-1/GIP dual receptor agonist, BGM0504, which showcased impressive reductions in various health indicators such as weight and triglycerides. The results are expected to contribute to advancements in cardiometabolic health management.

SUZHOU, China, May 7, 2026 /PRNewswire/ — Recently, BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as “BrightGene Bio-Medical ” or “the Company”) announced that its proprietary GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide) dual receptor agonist, BGM0504 injection, has achieved positive topline results from a Phase III clinical trial (CTR20243983/NCT06704581) evaluating its efficacy and safety in […]

Health BrightGene Bio-Medical clinical trial health GLP-1 cardiometabolic

Read original source →